

REMARKS

Claims 1 through 27 are pending in the application. All claims stand rejected under 35 USC §112, second paragraph, for assertedly being indefinite.

Amendment to claims is made herein without prejudice to the applicants' right to pursue claims of the same or similar scope in a duly filed continuing application.

I. The rejection of claims 1 through 14, 16 and 17

Claims 1 through 14, 16 and 17 were rejected for reciting "a therapeutically effective amount," but in the examiner's opinion, failing "to set forth the disorder that the therapeutic amount has been used for." [Office Action at p. 2] Despite the fact that the applicants believe that the instant application provides the first therapeutic use of the recited compound, and thus they are entitled to simply claim the composition in a pharmaceutical composition, *i.e.*, combined with a pharmaceutically acceptable carrier, claims 1, 5, 15 and 16 are amended herein to recite that the therapeutically effective amount of the tetraalkylammonium tetrathiomolybdate is effective to treat an angiogenic disorder only for purposes of expediting prosecution. Support for the amendment is found throughout the specification, for example, in the "Field of the Invention" and paragraph [0013] in the application as published.

Accordingly, the amendment obviates the rejection.

II. The rejection of claim 18 through 27

Claims 18 through 27 were rejected as assertedly being indefinite for reciting "at least one therapeutic agent that is different from tetraalkylammonium tetrathiomolybdate" and "at least one component of an assay system for determining serum ceruloplasmin levels." [Office Action at p. 2]

Claim 18 is amended first to indicate that the therapeutic agent an anti-cancer agent and an anti-angiogenic agent, both of which are agents well known in the art. See, for example, paragraph [0034] for description of anti-angiogenic agents, and paragraph [0038] for description of chemotherapeutic agents. Claim 18 is further amended to indicate that component for determining ceruloplasmin levels is one used in a ceruloplasmin oxidase

assay, which is taught in paragraph [0277] to be known in the art and evidence by the disclosures Brewer et al., 1987b, Brewer et al., 1987c, Brewer et al., 1989 and Sunderman and Nomoto, 1970, the complete citation of each provided in the specification and the documents themselves already of record in the application.

Accordingly, the applicants submit that the amendment obviates this rejection as well.

CONCLUSION

In view of the amendments and remarks made herein, the applicants believe that all claims are now in condition for allowance and respectfully request notification of the same.

Dated: April 27, 2009

Respectfully submitted,

By 

Joseph A. Williams, Jr.

Registration No.: 38,659

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant